Printer Friendly

Darling Named President at Anika Therapeutics.

M2 PHARMA-July 28, 2017-Darling Named President at Anika Therapeutics

(C)2017 M2 COMMUNICATIONS

- US-based orthopedic medicines company Anika Therapeutics, Inc. (NASDAQ: ANIK) has appointed orthopedic and medical device veteran Joseph Darling to the role of president, the company said.

For the past 15 years, the company's chief executive officer, Dr. Charles H. Sherwood served as president and plans to transition the role to Darling, while continuing his tenure as CEO.

Darling brings more than 20 years of executive management and leadership experience from publicly-traded, commercial-stage companies including Baxter Healthcare, Smith and Nephew, ConMed, and Wyeth-Ayerst.

Most recently, Darling held executive leadership positions with two small privately held orthopedic companies.

Prior to these roles, Darling held senior level executive positions at ConMed Corp., a global, publicly-held, diversified medical device company, as Global president of its wholly-owned subsidiary, Linvatec Corp., and as executive vice president of Global Corporate Commercial Operations.

At ConMed, Darling led five global business units with USD 760m in annual revenues and refocused organisational efforts in sales, marketing, and R and D.

Before ConMed, Darling was senior vice president and general manager for the sports medicine business at Smith and Nephew and played an important role in defining a global strategy that propelled the company to a leadership position in the sports medicine field.

Darling launched his career at Abbott Laboratories and Wyeth-Ayerst Pharmaceuticals, where he held management positions in sales and marketing before joining Baxter Healthcare as a vice president of marketing and health systems.

Anika Therapeutics is an integrated orthopedic medicines company based in Bedford, Massachusetts.

The company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid technology.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 28, 2017
Words:294
Previous Article:Slaoui Named to Moderna Therapeutics Board of Directors.
Next Article:European Commission grants marketing authorisation for Gilead's Vosevi to treat all genotypes of chronic hepatitis C.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters